Serving the Society Since 1986
Advanced Search
Volume 31 Issue 5
October 2016
    Citation: Fengling Luo, Tielong Chen, Jun Liu, Xihui Shen, Yinnan Zhao, Rongge Yang, Xiaolian Zhang. Ficolin-2 binds to HIV-1 gp120 and blocks viral infection .VIROLOGICA SINICA, 2016, 31(5) : 406-414.  http://dx.doi.org/10.1007/s12250-016-3808-3
    shu

    Ficolin-2 binds to HIV-1 gp120 and blocks viral infection

    • 1.

      The State Key Laboratory of Virology, Department of Immunology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, Wuhan University School of Medicine, Wuhan 430071, China

    • 2.

      Zhongnan Hospital of Wuhan University, Wuhan 430071, China

    • 3.

      Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China

    • Corresponding author: Rongge Yang, ryang@wh.iov.cn, ORCID: 0000-0002-6333-7941
      Xiaolian Zhang, zhangxiaolian@whu.edu.cn, ORCID: 0000-0002-8283-9381
    • Received Date: 13 May 2016
      Accepted Date: 02 August 2016
      Published Date: 29 August 2016
      Available online: 01 October 2016
    • Ficolin-2 is a lectin complement pathway activator present in normal human plasma and usually associated with infectious diseases, but little is known about the role of ficolin-2 in human immunodeficiency virus (HIV) infection. Here, we describe our novel findings that serum ficolin-2 concentrations of 103 HIV-1 patients were much higher compared to those of 57 healthy donors. In vitro analysis showed that HIV-1 infection could enhance ficolin-2 expression. We further demonstrated that recombinant ficolin-2 protein could bind with HIV-1 envelope glycoprotein gp120, and subsequently induce complement dependent cytotoxicity. Moreover, ficolin-2 could block the entry of HIV-1 into target cells (TZM-b1 and MT-2 cells) and infection in a ficolin-2 dosedependent manner. To our knowledge, this is the first report about the protective role of ficolin-2 against HIV-1 infection and our study suggests that ficolin-2 is an important human innate immune molecule against HIV.
    • 加载中

      1. Atkinson AP, Cedzynski M, Szemraj J, Swierzko A, BakRomaniszyn L, Banasik M, Zeman K, Matsushita M, Turner ML, Kilpatrick DC. 2004. L-ficolin in children with recurrent respiratory infections. Clin Exp Immunol, 138: 517-520.
          doi: 10.1111/cei.2004.138.issue-3

      2. Chapman SJ, Vannberg FO, Khor CC, Segal S, Moore CE, Knox K, Day NP, Davies RJ, Crook DW, Hill AV. 2007. Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease. Mol Immunol, 44: 3267-3270.
          doi: 10.1016/j.molimm.2006.04.013

      3. Chen T, Hu Y, Ding Q, Yu J, Wang F, Luo F, Zhang XL. 2015. Serum ficolin-2 concentrations are significantly changed in patients with hepatitis B virus infection and liver diseases. Virol Sin, 30: 249-260.
          doi: 10.1007/s12250-015-3605-4

      4. Dimitrov DS. 2000. Cell biology of virus entry. Cell, 10: 697-702.

      5. Endo Y, Sato Y, Matsushita M, Fujita T. 1996. Cloning and characterization of the human lectin P35 gene and its related gene. Genomics, 36: 515-521.
          doi: 10.1006/geno.1996.0497

      6. Ezekowitz RAB, Kuhlman M, Groopman JE, Byrn RA. 1989. A human serum mannose-binding protein inhibits in vitro infection by the human immunodeficiency virus. J Exp Med, 169: 185-196.
          doi: 10.1084/jem.169.1.185

      7. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. 2006. Mannosebinding lectin and its genetic variants. Genes Immun, 7: 85e94.

      8. Gilbert PB, McKeague IW, Eisen G, Mullins C, Guéye-NDiaye A, Mboup S, Kanki PJ. 2003. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med, 22: 573-593.
          doi: 10.1002/sim.1342

      9. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. 2009. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet, 373: 48-57.
          doi: 10.1016/S0140-6736(08)61697-9

      10. Haurum JS, Thiel S, Jones IM, Fische PB, Laursen SB, Jensenius JC. 1993. Complement activation upon binding of mannanbinding protein to HIV envelope glycoproteins. Aids, 7: 1307-1313.
          doi: 10.1097/00002030-199310000-00002

      11. Hoffmann JA, Kafatos FC, Janeway Jr. CA, Ezekowitz RAB. 1999. Phylogenetic perspectives in innate immunity. Science, 284: 1313-1318.
          doi: 10.1126/science.284.5418.1313

      12. Hummelshøj T, Thielens NM, Madsen HO, Arlaud GJ, Sim RB, Garred P. 2007. Molecular organization of human Ficolin-2. Mol Immunol, 44: 401-411.
          doi: 10.1016/j.molimm.2006.02.023

      13. Hu Q, Napier KB, Trent JO, Wang Z, Taylor S, Griffin GE, Peiper SC, Shattock RJ. 2005. Restricted Variable Residues in the Cterminal Segment of HIV-1 V3 Loop Regulate the Molecular Anatomy of CCR5 Utilization. J Mol Biol, 350: 699-712.
          doi: 10.1016/j.jmb.2005.05.024

      14. Ichijo H, Ronnstrand L, Miyagawa K, Ohashi H, Heldin CH, Miyazono K. 1991. Purification of transforming growth factorbeta 1 binding proteins from porcine uterus membranes. J Biol Chem, 266: 22459-22464.

      15. Keeffe JR, Gnanapragasam PNP, Gillespie SK, Yong J, Bjorkman PJ, Mayo SL. 2011. Designed oligomers of cyanovirin-N show enhanced HIV neutralization. P Natl Acad Sci USA, 108: 14079-14084.
          doi: 10.1073/pnas.1108777108

      16. Kilpatrick DC, McLintock LA, Allan EK, Copland M, Fujita T, Jordanides NE, Koch C, Matsushita M, Shiraki H, Stewart K, Tsujimura M, Turner ML. 2003. No strong relationship between mannan binding lectin or plasma ficolins and chemotherapyrelated infections. Clin Exp Immunol, 134: 279-284.
          doi: 10.1046/j.1365-2249.2003.02284.x

      17. Lars H, Tom E M, Thor U, Bjørn C, Pål A, Stig SF. 2003. Mannose-binding lectin in HIV infection: relation to disease progression and highly active antiretroviral therapy. JAIDS, 32: 354-361.

      18. Li GR, Liu J, Pan Q, Song ZB, Luo FL, Wang SR, Zhang XL, Zhou X. 2009. Synthesis and anti-HIV activity of [ddN]-[ddN] dimers and benzimidazole nucleoside dimers. Chem Biodivers, 6: 2200-2207.
          doi: 10.1002/(ISSN)1612-1880

      19. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, Anderson D, Montefiori D, Polacino P, Hu SL. 2008. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol, 82: 638-651.
          doi: 10.1128/JVI.01691-07

      20. Liu J, Ali MA, Shi Y, Zhao Y, Luo F, Yu J, Xiang T, Tang J, Li D, Hu Q, Ho W, Zhang XL. 2009. Specifically binding of Lficolin to N-glycans of HCV envelope glycoproteins E1 and E2 leads to complement activation. Cell Mol Immunol, 6: 235-244.
          doi: 10.1038/cmi.2009.32

      21. Liu Y, Endo Y, Iwaki D, Nakata M, Matsushita M, Wada I, Inoue K, Munakata M, Fujita T. 2005. Human M-ficolin is a secretory protein that activates the lectin complement pathway. J Immunol, 175: 3150-3156.
          doi: 10.4049/jimmunol.175.5.3150

      22. Lu J, Le Y. 1998. Ficolins and the fibrinogen-like domain. Immunobiology, 199: 190-199.
          doi: 10.1016/S0171-2985(98)80026-0

      23. Lu J, Le Y, Kon OL, Chan J, Lee SH. 1996. Biosynthesis of human ficolin, an Escherichia coli-binding protein, by monocytes: Comparison with the synthesis of two macrophage-specific proteins, C1q and the mannose receptor. Immunology, 89: 289-294.
          doi: 10.1046/j.1365-2567.1996.d01-732.x

      24. Matsushita M, Endo Y, Taira S, Sato Y, Fujita T, Ichikawa N, Nakata M, Mizuochi T. 1996. A novel human serum lectin with collagen-and fibrinogen-like domains that functions as an opsonin. J Biol Chem, 271: 2448-2454.
          doi: 10.1074/jbc.271.5.2448

      25. Pan Q, Chen H, Wang F, Jeza ViT, Hou W, Zhao Y, Xiang T, Zhu Y, EndoY, Fujita T, Zhang XL. 2012. L-ficolin binds to glycoproteins HA and NA and inhibits influenza A virus infection both in vitro and in vivo. J Innate Immun, 4: 312-324.
          doi: 10.1159/000335670

      26. Saarloos MN, Lint TF, Spear GT. 1995. Efficacy of HIV-specific and 'antibody-independent' mechanisms for complement activation by HIV-infected cells. Clin Exp Immunol, 99: 189-195.

      27. Sarma JV, Ward PA. 2011. The complement system. Cell Tissue Res, 343: 227-235.
          doi: 10.1007/s00441-010-1034-0

      28. Sugimoto R, Yae Y, Akaiwa M, Kitajima S, Shibata Y, Sato H, Hirata J, Okochi K, Izuhara K, Hamasaki N. 1998. Cloning and characterization of the Hakata antigen, a member of the ficolin/opsonin p35 lectin family. J Biol Chem, 273: 20721-20727.
          doi: 10.1074/jbc.273.33.20721

      29. Trujillo JR, Rogers R, Molina R M, Dangond F, McLane MF, Essex M, Brain JD. 2007. Noninfectious entry of HIV-1 into peripheral and brain macrophages mediated by the mannose receptor. Proc Natl Acad Sci USA, 104: 5097-5102.
          doi: 10.1073/pnas.0611263104

      30. Tullis RH, Duffin RP, Handley HH, Sodhi P, Menon J, Joyce JA, Kher V. 2009. Reduction of hepatitis C virus using Lectin affinity plasmapheresis in dialysis patients. Blood Purificat, 27: 64-69.

      31. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science, 280: 1884-1888.
          doi: 10.1126/science.280.5371.1884

      32. Williams BG, Granich R, Dye C. 2011. Role of acute infection in HIV transmission. Lancet, 378: 1913.
          doi: 10.1016/S0140-6736(11)61832-1

      33. Ying H, Ji X, Hart ML, Gupta K, Saifuddin M, Zariffard MR, Spear GT. 2004. Interaction of mannose-binding lectin with HIV type 1 is sufficient for virus opsonization but not neutralization. AIDS Res Hum Retroviruses, 20: 327-335.
          doi: 10.1089/088922204322996563

      34. Zhao Y, Ren Y, Zhang X, Zhao P, Tao W, Zhong J, Li Q, Zhang XL. 2014. Ficolin-2 inhibits Hepatitis C Virus infection, whereas apolipoprotein E3 mediates viral immune escape. J Immunol, 193: 783-796.
          doi: 10.4049/jimmunol.1302563

      35. Zhang XL, Liu M, Xie P, Wan S, Yea JT, Zhou X, Wu J. 2004. Specific inhibition effects of N-pentafluorobenzyl-1-deoxynojirimycin on human CD4+ T cells. Bioorg Med Chem Lett, 14: 3789-3792.
          doi: 10.1016/j.bmcl.2004.04.092

    • 加载中

    Figures(4)

    PDF

    Article Metrics

    Article views(6834) PDF downloads(26) Cited by()

    Related
    Proportional views

      Ficolin-2 binds to HIV-1 gp120 and blocks viral infection

        Corresponding author: Rongge Yang, ryang@wh.iov.cn
        Corresponding author: Xiaolian Zhang, zhangxiaolian@whu.edu.cn
      • 1. The State Key Laboratory of Virology, Department of Immunology and Hubei Province Key Laboratory of Allergy and Immune-related Diseases, Wuhan University School of Medicine, Wuhan 430071, China
      • 2. Zhongnan Hospital of Wuhan University, Wuhan 430071, China
      • 3. Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China
      • Received Date: 13 May 2016
      • Accepted Date: 02 August 2016
      • Published Date: 29 August 2016

      Abstract: Ficolin-2 is a lectin complement pathway activator present in normal human plasma and usually associated with infectious diseases, but little is known about the role of ficolin-2 in human immunodeficiency virus (HIV) infection. Here, we describe our novel findings that serum ficolin-2 concentrations of 103 HIV-1 patients were much higher compared to those of 57 healthy donors. In vitro analysis showed that HIV-1 infection could enhance ficolin-2 expression. We further demonstrated that recombinant ficolin-2 protein could bind with HIV-1 envelope glycoprotein gp120, and subsequently induce complement dependent cytotoxicity. Moreover, ficolin-2 could block the entry of HIV-1 into target cells (TZM-b1 and MT-2 cells) and infection in a ficolin-2 dosedependent manner. To our knowledge, this is the first report about the protective role of ficolin-2 against HIV-1 infection and our study suggests that ficolin-2 is an important human innate immune molecule against HIV.

        HTML

      INTRODUCTION